<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623649</url>
  </required_header>
  <id_info>
    <org_study_id>VCH 916-103</org_study_id>
    <nct_id>NCT00623649</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection</brief_title>
  <official_title>A Phase 1B, Multicentre, Randomized, Double-Blinded, and PLacebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and PK of Multiple Ascending Doses of VCH-916 in the Treatment Naive or Experienced Subjects With Chronic Hep C-Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViroChem Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a 3-day course of therapy with orally&#xD;
      administered VCH-916 given at different dosages can effectively reduce the amount of&#xD;
      circulating virus (i.e., viral load) in patients with early-stage chronic hepatitis&#xD;
      C-infection. This study will also evaluate the safety and tolerability of treatment with&#xD;
      VCH-916. Blood samples will also be taken to measure the levels of VCH-916 present in plasma&#xD;
      at various time points during the treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this trial is to assess the antiviral activity, safety, and tolerability of VCH-916 monotherapy in adult subjects with chronic HCV-infection.</measure>
    <time_frame>Day 1 to Day 17 visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic (PK) profile of VCH-916 in HCV-infected adults.</measure>
    <time_frame>Day 1 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the relationship between VCH-916 plasma levels and corresponding HCV RNA reduction with the administered dosages of VCH-916 in adults.</measure>
    <time_frame>Day 1 to Day 4 visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the kinetics of plasma HCV RNA following treatment for up to three(3) days with VCH-916.</measure>
    <time_frame>Day 1 to Day 4 visits</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCH-916 100 mg three times a day (t.i.d.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCH-916 200 mg (t.i.d.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCH-916 300 mg twice daily for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCH-916 400 mg twice daily for three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCH 916</intervention_name>
    <description>Dose escalation study with a full review of all safety data following each cohort.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose escalation study with a full review of all safety data following each cohort.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 to 60 years of age&#xD;
&#xD;
          -  No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3&#xD;
&#xD;
          -  Subject's liver disease is stable with ALT values &lt; 5 X ULN&#xD;
&#xD;
          -  Serologic evidence of detectable plasma HCV-RNA of ≥ 100,000 IU/ml at screening&#xD;
&#xD;
          -  Documented HCV Genotype 1 chronic hepatitis C.&#xD;
&#xD;
          -  Judged to be in good health on the basis of medical history and physical examination&#xD;
&#xD;
          -  All other hematology and clinical chemistry must be within normal limits or show no&#xD;
             clinically significant abnormalities.&#xD;
&#xD;
          -  Be treatment-naïve or experienced.&#xD;
&#xD;
          -  For female subjects, must not be pregnant or breastfeeding and must be postmenopausal,&#xD;
             surgically sterile, abstinent, or using two proven methods of birth control.&#xD;
&#xD;
          -  Sexually active male subjects, must be practicing acceptable methods of contraception&#xD;
             during the treatment period&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum ß-HCG pregnancy&#xD;
             test at screening and a negative urine pregnancy test on Day 1 before the first dose&#xD;
             of study drugs.&#xD;
&#xD;
          -  Agree not to participate in other clinical trials for the duration of his/her&#xD;
             participation in this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be participating in any other clinical studies or have participated in another&#xD;
             clinical trial within the last 30 days before study drug administration, or&#xD;
             participation in more than 2 drug studies in the last 12 months (exclusive of the&#xD;
             current study).&#xD;
&#xD;
          -  Be actively taking hard illicit drugs within 12 months prior to the screening visit or&#xD;
             alcohol.&#xD;
&#xD;
          -  Have a Child-Pugh score &gt; than 5.&#xD;
&#xD;
          -  Have evidence of liver cirrhosis including histological evidence of hepatic cirrhosis&#xD;
             on any liver biopsy.&#xD;
&#xD;
          -  Have any cause of liver disease other than chronic hepatitis C-infection&#xD;
&#xD;
          -  Active or malignant disease or suspicion or history of malignant disease within five&#xD;
             previous years (except for adequately treated basal cell carcinoma).&#xD;
&#xD;
          -  Have clinically significant electrocardiogram abnormalities and/or cardiovascular&#xD;
             dysfunction within the previous 6 months&#xD;
&#xD;
          -  Have significant renal, pulmonary, gastrointestinal absorption, or neurological&#xD;
             diseases, or neoplasia.&#xD;
&#xD;
          -  Have a history of psychiatric disorders determined by the investigator to&#xD;
             contraindicate therapy.&#xD;
&#xD;
          -  Have uncontrolled Type 1 or Type II diabetes.&#xD;
&#xD;
          -  Antinuclear antibody titer ≥1:320.&#xD;
&#xD;
          -  Coinfection with hepatitis B and/or HIV 1 or HIV 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McHutchison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Liver INstitute at Methodist Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

